The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panelcontaining genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).
Features and Benefits of AVENIO ctDNA Expanded Kit
Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
Includes reagents, bioinformatics and software
Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
Overview
The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panelcontaining genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).
Features and Benefits of AVENIO ctDNA Expanded Kit
Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
Includes reagents, bioinformatics and software
Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
Product Highlights
Accurate detection of all four classes of mutations with high sensitivity and specificity2,3
>99% sensitivity for all four classes of mutations
>99% positive predictive value (PPV) for indels, fusions and CNVs, and >98% PPV for SNVs
View the detailed Gene List for the AVENIO Expanded Panel
The Unique Challenges and Opportunities of Circulating Tumor DNA
Presenter: Dan Klass, Ph.D.
Roche
A portfolio of NGS liquid biopsy assays
The AVENIO ctDNA Expanded Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit for longitudinal tumor burden monitoring.